November 18, 2021
Life Sciences
  • The CMS extended the deadline for drugmakers to comply with the Trump-era regulation requiring them to calculate the “best price” for drugs under Medicaid’s drug rebate program using discounts they offer patients. The new final rule will officially delay best prices reporting from January 1, 2022, to July 1, 2022. July 1, 2022. The agency is also giving U.S. territories an additional nine months – until January 1, 2023 – to comply. (Rule here)